Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Immix Biopharma, Inc.

NASDAQ: IMMX · Life Sciences · 4 alerts · CIK 1873835

Share price
$7.48Close, Nov 16
Market cap
$627M
Shares outstanding
83.81MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Immix Biopharma, Inc. filings on SEC EDGAR ↗

7:00 AM ET 8-K
Clinical Trial Data

Immix Biopharma Clinical Trial Data

Immix Biopharma announced positive interim results from its Phase 2 NEXICART-2 clinical trial of NXC-201 in relapsed/refractory AL Amyloidosis, showing an 89% complete response rate across 45 patients. The company noted that MRD-negativity predicts future complete responses, potentially increasing the rate to 98%, and plans a BLA submission for the therapy in mid-2027.

Earnings call
Sep 29, 2026, 8:00 AM ET

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.